🚀 VC round data is live in beta, check it out!
SKAN Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for SKAN Group and similar public comparables like PROCEPT BioRobotics, Tandem Diabetes Care, Butterfly Network, NovoCure and more.
SKAN Group Overview
About SKAN Group
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. Its core competency is the design and development of process isolators for the aseptic filling of biopharmaceutical products. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, and transfer systems. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
Founded
1968
HQ
Employees
1.5K
Website
Financials (LTM)
EV
$1B
SKAN Group Financials
SKAN Group reported last 12-month revenue of $446M and EBITDA of $55M.
In the same LTM period, SKAN Group generated $343M in gross profit, $55M in EBITDA, and $27M in net income.
Revenue (LTM)
SKAN Group P&L
In the most recent fiscal year, SKAN Group reported revenue of $427M and EBITDA of $49M.
SKAN Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $446M | XXX | $427M | XXX | XXX | XXX |
| Gross Profit | $343M | XXX | $328M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 77% | XXX | XXX | XXX |
| EBITDA | $55M | XXX | $49M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $27M | XXX | $22M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Debt | — | — | $42M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
SKAN Group Stock Performance
SKAN Group has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
SKAN Group's stock price is $63.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.2% | XXX | XXX | XXX | $0.99 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSKAN Group Valuation Multiples
SKAN Group trades at 3.3x EV/Revenue multiple, and 26.7x EV/EBITDA.
EV / Revenue (LTM)
SKAN Group Financial Valuation Multiples
As of April 20, 2026, SKAN Group has market cap of $1B and EV of $1B.
Equity research analysts estimate SKAN Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SKAN Group has a P/E ratio of 51.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 3.3x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | 26.7x | XXX | 30.1x | XXX | XXX | XXX |
| EV/EBIT | 39.7x | XXX | 45.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | 4.5x | XXX | XXX | XXX |
| P/E | 51.8x | XXX | 64.0x | XXX | XXX | XXX |
| EV/FCF | (9624.7x) | XXX | 62.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SKAN Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
SKAN Group Margins & Growth Rates
SKAN Group's revenue in the last 12 month grew by 19%.
SKAN Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
SKAN Group's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SKAN Group's rule of X is 59% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
SKAN Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 36% | XXX | 42% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 59% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
SKAN Group Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| SKAN Group | XXX | XXX | XXX | XXX | XXX | XXX |
| PROCEPT BioRobotics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tandem Diabetes Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Butterfly Network | XXX | XXX | XXX | XXX | XXX | XXX |
| NovoCure | XXX | XXX | XXX | XXX | XXX | XXX |
| Subgen AI | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SKAN Group M&A Activity
SKAN Group acquired XXX companies to date.
Last acquisition by SKAN Group was on XXXXXXXX, XXXXX. SKAN Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by SKAN Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSKAN Group Investment Activity
SKAN Group invested in XXX companies to date.
SKAN Group made its latest investment on XXXXXXXX, XXXXX. SKAN Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by SKAN Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SKAN Group
| When was SKAN Group founded? | SKAN Group was founded in 1968. |
| Where is SKAN Group headquartered? | SKAN Group is headquartered in Switzerland. |
| How many employees does SKAN Group have? | As of today, SKAN Group has over 1K employees. |
| Who is the CEO of SKAN Group? | SKAN Group's CEO is Thomas Huber. |
| Is SKAN Group publicly listed? | Yes, SKAN Group is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of SKAN Group? | SKAN Group trades under SKAN ticker. |
| When did SKAN Group go public? | SKAN Group went public in 2021. |
| Who are competitors of SKAN Group? | SKAN Group main competitors are PROCEPT BioRobotics, Tandem Diabetes Care, Butterfly Network, NovoCure. |
| What is the current market cap of SKAN Group? | SKAN Group's current market cap is $1B. |
| What is the current revenue of SKAN Group? | SKAN Group's last 12 months revenue is $446M. |
| What is the current revenue growth of SKAN Group? | SKAN Group revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of SKAN Group? | Current revenue multiple of SKAN Group is 3.3x. |
| Is SKAN Group profitable? | Yes, SKAN Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SKAN Group? | SKAN Group's last 12 months EBITDA is $55M. |
| What is SKAN Group's EBITDA margin? | SKAN Group's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of SKAN Group? | Current EBITDA multiple of SKAN Group is 26.7x. |
| What is the current FCF of SKAN Group? | SKAN Group's last 12 months FCF is ($153K). |
| What is SKAN Group's FCF margin? | SKAN Group's last 12 months FCF margin is (0%). |
| What is the current EV/FCF multiple of SKAN Group? | Current FCF multiple of SKAN Group is (9624.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.